Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday
Key Points
This is Lyforli, a cancer treatment.
It was developed by the company using a unique approach focused on the hormone cortisol.
- 10 stocks we like better than Corcept Therapeutics ›
Corcept Therapeutics (NASDAQ: CORT) took its investors for quite a ride on Hump Day. The commercial-stage biotech earned its latest nod from a regulator that afternoon and, not surprisingly, its shares leaped skyward on the news. By the end of the day, they had risen by almost 20% in value.
The FDA says yes to Lifyorli
Corcept announced that the U.S. Food and Drug Administration (FDA) approved its Lifyorli, in combination with the chemotherapy drug nab-paclitaxel, for the treatment of the platinum-resistant stages of ovarian, fallopian tube, and primary peritoneal cancer. The approval covers adults who have previously been administered one to three prior systemic treatment regimens.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Image source: Getty Images.
According to the company, the FDA's green light was based on the encouraging outcomes of Lifyorli's Rosella trial. This involved 381 patients who were administered the combination therapy, or Lifyorli alone.
Corcept focuses on therapies involving the modulation of cortisol, the so-called "stress hormone" that regulates a number of the body's functions. It's clearly going to continue pursuing that strategy. The company quoted CEO Joseph Belanoff as saying that "Today's approval of Lifyorli is an important first step, but there is much more to explore with this new mode of treatment."
Betting on future wins
One advantage of the biotech sector is that its victories can be clear and significant. This isn't Corcept's first time at the rodeo (it received its first FDA approval in 2012), but Lifyorli's win not only gives the company a high-potential product in the cancer segment, but it also validates its unique focus on cortisol. I have no trouble imagining more approvals for the biotech in the coming years.
Should you buy stock in Corcept Therapeutics right now?
Before you buy stock in Corcept Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Corcept Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $490,325!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,074,070!*
Now, it’s worth noting Stock Advisor’s total average return is 900% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of March 25, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Corcept Therapeutics. The Motley Fool has a disclosure policy.
Recommended Articles
